Company intelligence / Profile preview

Nanorx

Baton Rouge, Louisiana, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Other

Overview

Nanorx develops proprietary nanoformulation technologies to improve the delivery and efficacy of pharmaceuticals across a range of therapeutic areas. Their lead innovations include GM1 nanomicelles for efficient encapsulation and protection of diverse drugs. They have developed Metadichol®, a nanoemulsion with potential applications in infectious disease prevention/treatment such as tuberculosis. No published results from large-scale clinical trials were found.

Therapeutic areas: OncologyEndocrinologyImmunologyHematologyDermatologyNeurologyInfectious Diseases
Modalities: NanoparticleLiposomeMicellePolymer-drug conjugate therapySmall molecule
Industry: Biotech

Drug pipeline

1 asset

metadichol

Indications: Diabetes

Beyond the preview

Go deeper on Nanorx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanorx.

Explore the full profile